Introduction
Anterior ischemic optic neuropathy (AION) is the most common acute optic neuropathy in patients over 50-years-old and typically leads to permanent vision loss. [1] [2] Although experts agree that non-arteritic AION results from ischemia of the optic nerve (ON) head, 1, 3 there is still significant controversy regarding the mechanism of disease 4 and there is currently no effective treatment. Photochemical thrombosis animal models of AION have been instrumental in elucidating the events following ON head ischemia. [5] [6] [7] [8] [9] In experimental AION, there is early glial and axonal dysfunction, with ON oligodendrocyte apoptosis occurring by day 6 and progressive nerve demyelination within 2 weeks. 5, 8, 9 Retinal ganglion cell (RGC) loss peaks during weeks 2 and 3. 7, 8, 10, 11 During these 3 weeks of critical period for treatment considerations, there are important signs of self repair, such as the upregulation of retinal heat shock proteins HSP 70, 84, and 86. 5, 8 Heat shock proteins act as molecular chaperones and are thought to have important roles in optic neuropathies, retinal diseases, and central nervous system inflammatory and neurodegenerative diseases. [12] [13] [14] [15] [16] In this study, we used a mouse model for AION via photochemical thrombosis [5] [6] [7] [8] 10, 11, 17 to examine the early changes following ON head ischemia. We then assessed the effectiveness of a small heat shock protein named aB-crystallin (aBC) in the treatment of experimental AION, using functional and histological approaches.
Materials and methods

Animals, care, and sedation
All animal care and experiments were carried out in accordance with the ARVO guideline for the Use of Animals in Ophthalmic and Vision Research and the Stanford Administrative Panel on Laboratory Animal Care. Adult wild-type 129S2/Sv mice were purchased (Charles River, Wilmington, MA, USA; Taconic Farm, Hudson, NY, USA) and housed in a 12-h light/12-h dark cycle with food and water ad libitum. All procedures were performed under sedation, achieved with ketamine 50-100 mg/kg, xylazine 2-5 mg/kg, and buprenorphine 0.05 mg/kg.
Experimental AION
Our model of experimental AION is a modification of previously published studies. [5] [6] [7] [8] 10, 11, 17 After rose bengal (1.25 mM in PBS, 2 ml per g body weight) injection via tail vein, the ON head was exposed to 20 light spots (frequency doubled Nd:YAG laser, Pascal, OptiMedica, Santa Clara, CA, USA), each with 100 mm diameter (equivalent to 39 mm on the nerve), at a power of 35 mW and duration of 500 ms. We delivered small laser spots at low power and shorter duration circumferentially around the ON head in order to focus more precisely while covering the entire ON head. The degree and extent of whitening due to ischemia 18 are similar to that of the Bernstein model in our direct comparison. As reported previously, 5, 8 application of the laser in the absence of rose bengal did not cause significant ischemia.
Western blotting
Protein was prepared from the ON head and sensory retina of three pairs of eyes from adult mice 1 day post-AION per routine protocol in the presence of protease inhibitors. Protein concentrations were determined using micro BCA kit (Pierce, Rockford, IL, USA). Equal amount of protein per lane was loaded onto a 10% mini-SDS-PAGE gel (Invitrogen, Carlsbad, CA, USA) and run as per the recommended protocol. Western blotting was carried out with anti-aBC rabbit polyclonal antibody (1 : 200 dilution, Abcam, Cambridge, MA, USA) and anti-class III b-tubulin monoclonal antibody (1 : 500 dilution, Abcam) and developed per the ECL protocol (Pierce). Four experiments for each antibody were scanned under equal conditions and quantified with Image J (http://imagej.nih.gov/). Student's paired t-test was used for statistical analysis, and all error bars are in SEM.
Immunohistochemistry and morphometric analyses
At each time point, we performed intracardiac perfusion (India ink for angiogram, 4% paraformaldehyde in PBS for fixation) and whole mount neuroretinal dissection. For immunofluorescence microscopy, primary antibody with anti-Iba-1 rabbit polyclonal antibody (1 : 500-1000 dilutions, WAKO, Richmond, VA, USA) or anti-glial fibrillary acidic protein (GFAP) monoclonal antibody (1 : 500-1000 dilutions, Sigma, St Louis, MO, USA) and goat anti-rabbit or anti-mouse IgG secondary antibodies (1 : 200-400 dilutions, Invitrogen) were used. The retinas were mounted with Vectashield containing DAPI (Vector Labs, Burlingame, CA, USA). For paraffin-embedded or frozen horizontal sections, the eyes and ONs were dissected, and 10 mm horizontal sections were prepared and H and E stained. All morphometric analysis was performed under masked condition so the identity of the data was not known. A circular area (300 pixel radius) centered at the ON head was quantified with Image J. Following background subtraction, regions of interest were multiplied by the intensity to calculate the intensity * pixel 2 . For each pair of eyes, the AION eye was normalized to the unlasered eye, which served as control for every step of the experiment. Statistical significance between the lasered and unlasered eyes was determined using paired Student's t-test and between saline and aBC-treated groups, unpaired t-test.
aBC treatment
For intravenous treatment, 10 mg of recombinant aBC (U.S. Biological, Swampscott, MA, USA) vs saline alone (final volume 100 ml) was injected into the tail vein under masked conditions within 5 h of AION. For short-term treatment, the animals were injected once per day for 3 days. For longer treatments, the animals were injected every other day for 3 weeks. Animals in the experimental and control groups received same number of injections. To see if intravitreal injection of aBC led to additional benefit compared with intravenous injections alone, we performed intravitreal injection of 2 mg aBC or saline (final volume 1 ml) given to each eye within 5 h of AION in addition to intravenous injections.
Intracranial electrode implantation
Small burr holes were drilled in the skull overlying the visual cortex on each side (2.5-3 mm parasagittal and 2-3 mm anterior to the lambdoid suture 19, 20 ) for placement of small stainless steel screw electrodes (JI Morris, Southbridge, MA, USA). Dental cement secured the electrodes over the skull, with several sutures to close the scalp. Implanted mice behaved like unimplanted mice, with normal response to stimuli, locomotion and weight gain over months. Figure 3a to illustrate responses over a large range of luminance intensities. There were no fVEP responses when both eyes were occluded. The recordings were conducted while masked to the treatment given.
The amplitude and latency of N 1 , the dominant fVEP waveform, were averaged from 30-50 trials (minimum of three trials/mouse/time point) from six animals per treatment group, where good recording was performed in every time point. Data analysis was restricted to luminance intensities between 2.15-20 cd s/m 2 . Raw amplitude was calculated as difference between baseline and N 1 peak ranged between 3-50 mV. The latency was calculated as time to N 1 peak from stimulus onset and ranged between 30-80 ms. Although latencies for N 1 were extremely stable across several examinations in each mouse, their raw amplitudes showed more variability. Data were analyzed with Excel and Origin, Grubbs' test was used to eliminate outliers (0-3 per data point), and statistical differences were determined using Student's t-test and one-way ANOVA.
RGC quantification
H and E stained horizontal sections of the posterior pole were photographed with a Â 40 objective. Under masked conditions, the number of cells in the RGC layer per high power field was quantified using Image J. Following color deconvolution, the entire RGC layer was counted with nucleus counter, using a size threshold of 500 pixels, and then visually confirmed. Statistical significance was determined using unpaired Student's t-test.
ON oligodendrocyte quantification
We stained for oligodendrocytes with anti-CC1 mAb antibody (Calbiochem, Gibbstown, NJ, USA), goat anti-mouse secondary antibody, and mounted with DAPI-containing Vectorshield medium (Vector Labs). We photographed the first 500 mm of the myelinated ONs and used image J to quantify the number of cells that were CC1-negative and DAPI-positive, which represented oligodendrocytes. CC1 antibody staining did not overlap with that of GFAP expression in astrocytes. Statistical significance was determined using unpaired Student's t-test.
Statement of ethics
We certify that all applicable institutional and governmental regulations concerning the ethical use of animals were followed during this research.
Results
Early post-AION upregulation of aBC
Immediately following experimental AION, there was loss of peripapillary microvasculature, swelling, and leakage at the ON head (Figure 1a ). At day-1 following AION, western blot analysis (Figure 1b-c) revealed an upregulation of aBC protein in the ON head and neuroretina compared with control eyes (n ¼ 4 experiments, Po0.03), but no significant change in the expression of class-III b-tubulin, a major component of the neuronal microtubule that is highly expressed in RGCs. Consistent with the idea that aBC is important in inflammation, 15, 21 we found that on post-ischemia day 3, there was increased ON head Iba-1 staining (data not shown, n ¼ 5, see Figure 2 ), which suggested microglial activation, and elevated GFAP expression (data not shown, n ¼ 5, see Figure 2 ), which correlated with astrocytic activation. These findings resembled changes after laser-induced photochemical thrombosis in the retina 22 and axonal ischemia near the retina-ON junction 23 and the brain. 24 Our data indicated that aBC was an early marker following experimental AION, which may serve as part of the endogenous protective mechanism.
Short-term aBC treatment
To test this hypothesis, we performed short-term and long-term aBC treatment following experimental AION in adult mice. For short-term treatment, animals received daily intravenous injections of aBC (10 mg per injection) vs phosphate-buffered saline (PBS) alone for 3 days, and we performed immunohistochemistry and analyzed whole mount retina for ON head staining with Iba-1 antibody for microglia and with anti-GFAP antibody for astrocytes. In the PBS-treated group, like in non-treated eyes, the Iba-1 expression following AION was significantly increased compared with that of the control
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Eye eyes (AION/control: 298 ± 62%, n ¼ 8 pairs of eyes, Po0.002) (Figures 2 a and b) . This was consistent with post-AION microglial activation. The aBC treatment effectively suppressed this microglial activation (Po0.05) (Figure 2c ), suggesting that aBC decreased post-AION inflammation. Similar to Iba-1 antibody staining, the ON To monitor visual function, we recorded serial photopic flash VEP responses using electrodes implanted in the occipital lobes. Monocular light stimulation led to prominent contralateral occipital cortical responses, 20 with increasing amplitudes and decreasing latencies of the N 1 dominant peak in response to increasing luminance intensities (Figure 3a) . We compared responses with 20 cd s/m 2 , the brightest light stimuli used, between the aBC-treated and the control groups. Compared with baseline, at days 1-2 post-AION, there was a significant decrease of fVEP amplitudes in both saline-(baseline: 14.2±1.3 mV; days 1-2: 9.8±0.2 mV; P ¼ 0.02, n ¼ 6) and aBC-treated (baseline: 15.1±1.0 mV; days 1-2: 11.7 ± 1.3 mV; P ¼ 0.04, n ¼ 6) groups (Figure 3b-c) . There was no change in the latency of responses in both groups (saline: P ¼ 0.7; aBC: P ¼ 0.3) (Figure 3b-c) . These findings suggested that short-term aBC treatment did not improve ON function early after experimental AION. 
Long-term aBC treatment
For long-term treatment, we injected adult mice intravenously with aBC (10 mg per injection) every other day for 3 weeks. Control group was injected with saline alone, and injections were performed under masked condition. We used fVEP recording to monitor visual function weekly over 3 weeks. Compared with days 1-2, at week 1, the fVEP amplitudes in the control group improved back to baseline (compared with days 1-2, Po0.001; compared with baseline, P ¼ 0.2) whereas the aBC-treated group had persistently low amplitudes (compared with days 1-2, P40.5; compared with baseline, P ¼ 0.07). There was variability in the fVEP amplitudes throughout the 3 weeks, with overall improvement in both control and aBC-treated groups at 3 weeks compared with immediately post-AION.
The most striking finding in the long-term aBC experiment was the fVEP latencies, which typically showed much less variability compared with the fVEP amplitudes. Compared with days 1-2, by week 1, the aBC-treated group demonstrated decreased response latencies (baseline: 52.2 ± 1.1 ms; week 1: 50.1 ± 1.2 ms; Po0.05, n ¼ 6) while the latencies in the saline-treated group actually increased (baseline: 51.1±0.6 ms; week 1: 53.7±0.9 ms; Po0.05, n ¼ 6). This acceleration of fVEP latencies in the aBC-treated group continued at weeks 2 and 3 (Figure 3c, right) . Comparing the two treatment groups, the latency improvement in the aBC-treated group was significant at week 1 (P ¼ 0.02), week 2 (P ¼ 0.002) and week 3 (P ¼ 0.009). By the third week of aBC treatment, fVEP latencies at 20 cd s/m 2 were faster by 5.2 ms compared with days 1-2 (d1-2: 52.1±1.3 ms, week 3: 46.9 ± 1.3 ms, P ¼ 0.02), whereas the latencies in the saline-treated group remained unchanged (P ¼ 0.3).
Compared with baseline, the improvement of fVEP latency in the aBC-treated group at week 3 was evident across multiple luminance intensities (Figure 3d, right (Figure 3d, left) . These findings supported a significant functional improvement of the speed but not the amplitude of the visually evoked responses during the 3-week aBC treatment.
aBC rescued ON oligodendrocytes but not RGCs
We looked to see if the fVEP improvement in the aBC-treated group correlated with greater RGC survival. A total of 52 ± 5 fields were counted for the AION and control eyes in both treatment groups. At week 3, there was a significant loss of RGC layer cells 5, 8 in the AION eyes compared with the controlled eyes in both the aBC-treated group and in the control group (Po0.001 between AION and controlled eyes for both treatment groups) and no difference between the 2 treatment groups ( Figure 4) .
As fVEP latency is affected by myelination and the number and function of the ON oligodendrocytes, we analyzed if long-term intravenous aBC (10 mg, every other day) vs saline treatment differentially affected ON oligodendrocyte survival. This is particularly important since weeks 1-2, when the fVEP latency started to differ between the aBC-treated group compared with the control group, is known to be a peak period of ON oligodendrocytes loss following AION. 8 In case the intravenously delivered aBC did not reach the ON head due to vascular compromise, we also looked at the effect of additional intravitreal aBC injection, which should deliver sufficient aBC to the ON head. On day 9 after treatment, during time of peak post-AION oligodendrocyte loss, 8 we counted the number of cells that stained positive for CC1 and DAPI, which corresponded to the number of oligodendrocytes. In the intravenous saline-treated group, there was 25% fewer oligodendrocytes in the post-AION ONs compared with the control ONs (control: 9.7±1 cells/mm A combination of intravenous and intravitreal aBC treatment also resulted in complete rescue of the ON oligodendrocytes following AION and significant improvement compared with the saline-treated group (n ¼ 5-11 fields per condition per group, P ¼ 0.005). These data showed that aBC treatment promoted survival of ON oligodendrocytes, which correlated in timing with the significant fVEP latency improvement at weeks 1-2.
Discussion
Experimental AION led to early ON head swelling, loss of peripapillary vessels, 1,2 upregulation of micro-and macroglia, and decreased fVEP responses. 25, 26 The upregulation of aBC, a molecular chaperone important in retinal ischemia, experimental glaucoma, and central nervous system inflammatory disease, [14] [15] [16] 27 following experimental AION was consistent with its role as a endogenous protective mechanism. [28] [29] [30] Consistent with this idea, early, 3-day intravenous aBC treatment dampened post-AION microglial activation, although it did not impact fVEP responses on days 1-2. Three-week aBC treatment, however, led to significant improvement of the latency of the fVEP responses as early as week 1, which was maintained at weeks 2 and 3. This acceleration of the visually evoked responses correlated with the rescue of the ON oligodendrocytes on day 9 but not survival of RGCs at week 3. Intravenous treatment was as efficacious as intravenous plus intravitreal treatment. Taken together, our data suggested an ON protective effect of aBC following ON head ischemia by dampening inflammation and salvaging oligodendrocytes.
Expressed in the RGCs 34 and ON glia, 16 aBC is poised to have a role in optic neuropathies. The upregulation of aBC immediately following ON head ischemia is consistent with its function as a small heat shock protein with both protective and anti-apoptotic actions.
14-16 Historically known as the predominant structural proteins in the lens, the a-crystallins have been shown to act as molecular chaperones like Hsp70 and GroE, 14 and aBC protects against UVA-induced apoptosis in cultured human lens epithelium. An upregulation of aBC has also been seen in response to hypoxia in cultured human ON head astrocytes, 35 oxidative stress in cultured trabecular meshwork, 36 chemical hypoxia in retina, 37 and oxidative stress in cultured retinal pigment epithelium. 38 Furthermore, aBC upregulation may prevent apoptosis from oxidative stress in photoreceptors in uveitis. 39 In the absence of aBC, retinal pigment epithelium is more susceptible to H 2 O 2 -induced apoptosis 37 and exhibits greater post-ischemic inflammatory changes at the ON head, supporting aBC's role as a negative regulator of inflammation (this report). In contrast, progressive RGC degeneration observed in the ocular hypertension rat model for glaucomatous neuropathy is associated with a temporary downregulation of aBC after 2 weeks and recovery after 5 weeks, [31] [32] [33] suggesting a transient negative effect of ocular hypertension on aBC gene expression. 32 The improvement in fVEPs responses following aBC treatment developed over 3 weeks, during a period of known axonal and oligodendrocyte loss. 8 The rescue of ON oligodendrocytes but not RGCs following experimental AION suggested that aBC acted by protecting the ON but not neurons, presumably associated with an increased ratio of oligodendrocytes to axons in the ON. Curiously, fVEP latencies in the aBC-treated group improved beyond that of the baseline, which may be related to the direct effects of aBC or from aBC-facilitated developmental acceleration of VEP latency. 40 Aside from the effects on ON oligodendrocytes, we cannot rule out that aBC treatment may have led to the selective survival of faster conducting RGCs, such as the parasol cells, over those of the slower conducting cells, such as the midget cells, 41 which could explain the decreased latencies observed in the aBC treated mice. Although the melanopsin-containing RGCs are known to be more resistant to ischemia, they do not contribute to evoked responses in the occipital lobe and therefore cannot account for the VEP latency changes.
Interestingly, aBC treatment significantly improved paralysis and reduced inflammation in the central nervous system in an animal model of multiple sclerosis, 15 a disease, which is also associated with VEP prolongation due to axonal and oligodendrocyte dysfunction. Injection of aBC intravitreally has also been shown to improve ON axon density following crush injury. 42 Here we provided compelling histological and functional evidence for the potential therapeutic value of a novel treatment aBC in AION.
